UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 冠動脈ステント血栓症：臨床症状およびマネージメントcoronary artery stent thrombosis clinical presentation and management [show details]
…will be noted. Patients with stent thrombosis usually present with an acute coronary syndrome (ACS; unstable angina, non-ST elevation myocardial infarction [NSTEMI], or ST-elevation MI [STEMI]). In most …
2. 冠動脈ステント血栓症：発症率および危険因子coronary artery stent thrombosis incidence and risk factors [show details]
… characteristics: ST- or non-ST elevation myocardial infarction (MI) (both compared with stable angina), thrombus at baseline, and bifurcation lesions . The clinical presentation and management of IPST is discussed …
3. ST上昇型心筋梗塞の急性期マネージメントの概要overview of the acute management of st elevation myocardial infarction [show details]
…hospital admission include non-ST elevation acute coronary syndrome, surgery, respiratory failure, and percutaneous coronary intervention (complicated by stent thrombosis). Coronary angiography and percutaneous …
4. ST上昇型心筋梗塞の非急性期マネージメントの概要overview of the non acute management of st elevation myocardial infarction [show details]
…rehabilitation facility. Patients presenting with a non-ST elevation myocardial infarction have a lower in-hospital mortality than those with an ST elevation myocardial infarction, but a similar or perhaps …
5. 前立腺癌の遺伝的危険因子genetic risk factors for prostate cancer [show details]
…tumor; Two consensus conferences have addressed emerging areas in genetic counseling and genetic testing for prostate cancer: the St. Gallen Advanced Prostate Cancer Consensus Conference 2017 and the …

English Journal

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.

Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Heinrich D, Higano CTS, Hofman MS, Hussain M, James N, Kanesvaran R, Kantoff P, Khauli RB, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Reiter RE, Roach M, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Small E, Smith M, Soule H, Sternberg CN, Steuber T, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tombal B, Türkeri L, van Oort I, Zapatero A, Omlin A.
European urology. 2020 Apr;77(4)508-547.
Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform clinical practice. The Advanced Prostate Cancer Consensus Conference (APCCC) 2019 addressed so
PMID 32001144

EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees.

Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Der Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, J L De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, J G Oyen W, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A.
European urology. 2020 Feb;77(2)223-250.
Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder
PMID 31753752

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B.
Annals of oncology : official journal of the European Society for Medical Oncology. 2019 12;30(12)e3.
PMID 32041688

Japanese Journal

乳腺神経内分泌癌の一例

関真理,園尾博司,齋藤亙,小池良和,太田裕介,山下哲正,下登志朗,山本裕,田中克浩,紅林淳一,秋山隆
川崎医学会誌 = Kawasaki medical journal 41(1), 75-82, 2015
稀な癌である乳腺神経内分泌癌(neuroendocrine carcinoma:以下NEC)を経験したので報告する.患者は35歳の女性で,右乳頭直下に腫瘤を自覚し当科を受診した.画像診断で乳癌を疑い,細胞診では乳頭腺管癌あるいは硬癌が推定された.針生検で浸潤性乳管癌と診断し,乳房温存術とセンチネルリンパ節生検を施行した.腫瘍は乳腺原発であり,組織像は,小細胞癌などの神経内分泌癌に類似していた.免疫 …
NAID 110009924811

St.Gallen 2007 リスク分類の特徴・注意点 (特集 St.Gallen2007に基づいた乳癌テーラーメイド補助療法)

池田正,鴨宣之
臨床外科 63(8), 1049-1054, 2008-08
NAID 40016166316

HER-2 (c-erbB-2) Test Update: Present Status and Problems

Tsuda Hitoshi
Breast Cancer 13(3), 236-248, 2006
… It is also noteworthy that a the St. Gallen International Consensus Conference 2005, HER-2 protein overexpression or HER-2 gene amplification has been included as an indicator for higher risk of recurrence for both node-negative and node-positive breast cancers. …
NAID 130004467445